Phase I/II Open Label, Multicentre Clinical Trial to Assess Safety and Efficacy of AAVLK03hOTC for Paediatric Patients With Ornithine Transcarbamylase Deficiency
Latest Information Update: 11 Mar 2026
At a glance
- Drugs BGT OTCD (Primary)
- Indications Ornithine carbamoyltransferase deficiency disease
- Focus Adverse reactions; First in man
- Acronyms HORACE
Most Recent Events
- 11 Mar 2026 New trial record
- 16 Nov 2023 Status changed from not yet recruiting to recruiting, according to a Bloomsbury Genetic Therapies Limited media release.